| Michael A. Martino |
Michael A. Martino was the founder of Arzeda Corp., a company founded in 2008, where he held the title of President & Chief Executive Officer from 2008 to 2011. He is currently the CEO, Chief Financial Officer, Secretary & Director at Ampio Pharmaceuticals, Inc., the Chief Executive Officer & Director at HemaFlo Therapeutics, Inc., a Director at Ambit Biosciences Corp., and a Director at CaraVan Biologix. Mr. Martino's former positions include being the President & Chief Executive Officer of Sonus Pharmaceuticals, Inc. from 1998 to 2008, the President, Chief Executive Officer & Director of Ambit Biosciences Corp. from 2011 to 2014, and the SVP-Innovation, Business Development & Strategy at CareFusion Corp. He also served as a Director at OncoGenex Pharmaceuticals, Inc., Excision BioTherapeutics, Inc., and the Technology Alliance. Additionally, Mr. Martino was the Chairman of the Washington Biotechnology & Biomedical Association and held the position of VP-Strategic Planning & Corporate Development at Mallinckrodt Medical, Inc. from 1983 to 1998. He served as a Trustee at Roanoke College from 2016 to 2020. Mr. Martino obtained an undergraduate degree from Roanoke College and an MBA from Virginia Polytechnic Institute & State University. |
| J. Kevin Buchi |
J. Kevin Buchi is currently the Chairman at Ampio Pharmaceuticals, Inc. and the Independent Non-Executive Director at Benitec Biopharma Ltd., Amneal Intermediate, Inc., Benitec Biopharma, Inc., and Amneal Pharmaceuticals, Inc. He previously held positions as the President, Chief Executive Officer & Director at Cephalon, Inc., BioSpecifics Technologies Corp., TetraLogic Pharmaceuticals Corp., and Dicerna Pharmaceuticals, Inc. He also served as the Director at Encysive Pharmaceuticals, Inc., Aptose Biosciences, Inc., Impax Laboratories LLC, Alexza Pharmaceuticals, Inc., Celator Pharmaceuticals, Inc., Stemline Therapeutics, Inc., Arana Therapeutics Ltd., ChemGenex Pharmaceuticals Pty Ltd., Mesoblast Ltd., Alaunos Therapeutics, Inc., Forward Pharma A, Zalicus, Inc., EPIRUS Biopharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd. Mr. Buchi received his undergraduate degree from Cornell University in 1976 and his graduate degree from Kellogg School of Management in 1980. |
| Daniel G. Stokely |
Daniel G. Stokely is currently the Chief Financial Officer & Secretary at Ampio Pharmaceuticals, Inc. He previously worked as a Controller at Elan Corp. Plc, a Controller at Dura Pharmaceuticals, Inc., and as the Chief Financial Officer & Controller at Wireless Facilities, Inc. He also served as a Principal at Deloitte & Touche LLP and as the Chief Accounting Officer & Vice President-Finance at Victory Pharma, Inc. Additionally, he held the position of Chief Financial Officer & Executive Vice President at Sentynl Therapeutics, Inc. Mr. Stokely obtained his undergraduate degree from San Diego State University. |
| Howard Levy |
Howard Levy is currently a Member of the Society of Critical Care Medicine and the Chief Medical Officer at Ampio Pharmaceuticals, Inc. He previously worked as a Medical Director-Acute Care at Eli Lilly & Co., Senior Director-Global Medical Program at CSL Behring LLC, Chief Medical Officer at Inspiration Biopharmaceuticals, Inc., Chief Medical Officer at Sangart, Inc., Chief-Critical Care Medicine at The University of New Mexico, and Associate VP-Clinical Research & Medical at Novo Nordisk, Inc. He also served as the Chief Medical Officer at Catalyst Biosciences, Inc. from 2016 to 2021. Dr. Levy holds a graduate degree from Carnegie Mellon University and a doctorate from the University of the Witwatersrand. |
| Elizabeth Varki Jobes |
Ms. Elizabeth V. Jobes is a Vice President-Compliance at Immunocore Holdings Plc, an Independent Director at Blue Foundry Bancorp, an Independent Director at Ampio Pharmaceuticals, Inc., a Global Chief Compliance Officer & Senior VP at Amryt Pharma Plc and a Treasurer & Director at Aegerion Pharmaceuticals, Inc. She is on the Board of Directors at Blue Foundry Bancorp, Blue Foundry Bank, Ampio Pharmaceuticals, Inc., Eyam Vaccines & Immunotherapeutics Ltd., South Asian Bar Association of North America and Aegerion Pharmaceuticals, Inc. Ms. Jobes was previously employed as a Global Chief Compliance Officer & Senior VP by Amryt Pharma Holdings Ltd., a Chief Compliance Officer-North America & SVP by EMD Serono, Inc., a Chief Compliance Officer & Senior Vice President by Auxilium Pharmaceuticals LLC, a Chief Compliance Officer & Vice President by Adolor Corp., a Senior Director-Global Compliance by Cephalon, Inc., a Chief-Repeat Violent Offenders Unit by City of Philadelphia (Pennsylvania), and a Global Chief Compliance Officer & Legal Counsel by Spark Therapeutics, Inc. She also served on the board at Women's Way. She received her undergraduate degree from The Pennsylvania State University and a graduate degree from Rutgers Law School. |
| David R. Stevens |
David R. Stevens is currently the Chairman at Advanced Headache Intervention, Inc. He is also an Independent Director at Ampio Pharmaceuticals, Inc. and a Director at Cetya Therapeutics, Inc. Previously, Dr. Stevens served as the President & Chief Executive Officer at Deprenyl Animal Health, Inc. from 1990 to 1998. He was also the Executive Chairman at Surginetics LLC, Chairman at CanCog Technologies, Inc., and Executive Chairman at Cedus, Inc. from 2012 to 2014. Additionally, he held the position of Director at Poniard Pharmaceuticals, Inc. from 2004 to 2013 and Director at Smart Drug Systems, Inc. from 1999 to 2006. He served as a Non-Executive Director at AquaBounty Technologies, Inc. from 2002 to 2012 and as a Director at Micro-Imaging Solutions LLC from 2007 to 2018. Furthermore, he was the Vice President-Research & Development at Agrion Corp. from 1986 to 1988. Dr. Stevens obtained a doctorate degree from the University of California, Davis and holds undergraduate and doctorate degrees from Washington State University. |
